Webinar Date/Time: Thu, Jun 13, 2024 11:00 AM EDT
Are you interested in the analytical development of monoclonal antibodies (mAbs)? USP Biologics presents a webinar with case studies and supporting data to help you navigate through the analytical procedures used to evaluate the quality attributes of mAbs for therapeutic use.
Register Free: https://www.biopharminternational.com/bp_w/standards-to-support
Event Overview:
The development of monoclonal antibodies (mAbs) is marked by impurities such as host cell proteins and residual DNA. USP offers solutions to evaluate the quality attributes of mAbs for therapeutic use.
Join this webinar to learn more about the validated methods that are described in USP–NF General Chapter <129> Analytical Procedures For Recombinant Therapeutic Monoclonal Antibodies, which include purity determination by size-exclusion chromatography (SEC), capillary electrophoresis, and analysis of glycans. Analytical procedures for mAbs using SEC-UHPLC and its inclusion in chapter <129> and the multi-attribute method (MAM) are also reviewed and demonstrated through case studies, and USP’s solutions to detect process-related impurities are discussed.
Key Learning Objectives:
Who Should Attend:
Speakers:
Niomi Peckham
Director of Pipeline Development, Global Biologics
United States Pharmacopeia
Niomi Peckham is Director of Pipeline Development in USP Global Biologics. The Pipeline Development team works with scientific experts and stakeholders to develop physical and documentary standards used to support development and quality assessment of biopharmaceuticals.
Ms Peckham has worked for several biotechnology and diagnostic companies but has spent most of her career at Pfizer and Alexion Pharmaceuticals, focusing on development of protein-based biopharmaceuticals. She has been responsible for development, validation, transfer, and lifecycle management of analytical methods for biopharmaceuticals from pre-clinical development through commercialization. She has had a particular focus on analysis of monoclonal antibodies and host cell proteins.
Ms Peckham holds a Bachelor of Science in Biotechnology from the University of Connecticut, a Master of Science in Molecular and Cellular Biology from SUNY Stony Brook, and a Graduate Certificate in Drug Development from Temple University.
Li Jing
Principal Scientist, Global Biologics
United States Pharmacopeia
Dr Li Jing is a Senior Manager in USP’s Global Biologics Department. Dr. Jing leads a team of liaisons working with the USP Expert Committees and multiple expert panels for proteins, peptides, and carbohydrates to develop standards that support biopharmaceutical quality assessment and development. Recently, Dr Jing worked with USP MAM Expert Panel and developed General Chapter <1060> Mass Spectrometry Based Multi-Attribute Method for Therapeutic Proteins.
Dr Jing holds a PhD in Analytical Chemistry from the University of Georgia, and a Bachelor of Science in Chemistry from Fudan University. She has worked for several biotechnology and pharmaceutical companies, focusing on the development of protein therapeutics and vaccine candidates.
Register Free: https://www.biopharminternational.com/bp_w/standards-to-support
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.